THR-18, a 18-mer peptide derived from PAI-1, is neuroprotective and improves thrombolysis by tPA in rat stroke models

Neurological Research

Volumn 33, Issue 9, 2011, Pages 983-990

  Krakovsky, M ^a   Polianski, V ^a   Nimrod, Abraham ^b   Higazi, A ^c   Leker, R R ^c   Lamensdorf, I ^b  

^a PharmaSeed Ltd   (Israel)

^b Thrombotech Ltd   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

Neuroprotection; PAI 1; Stroke; Thrombolysis; tPA

Indexed keywords

ACYLARGINYLMETHIONYLALANYLPROLYLGLUTAMYLGLUTAMYLISOLEUCYLISOLEUCYLMETHIONYLASPARTYLARGINYLPROLYLPHENYLALANYLLEUCYLTYROSYLVALYLVALYLARGINILAMIDE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BRAIN BLOOD FLOW; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; COGNITION; CONTROLLED STUDY; DRUG EFFECT; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; RAT; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

ANIMALS; BRAIN EDEMA; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; INTRACRANIAL HEMORRHAGES; MALE; NEUROPROTECTIVE AGENTS; PEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; STROKE; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 80855140385     PISSN: 01616412     EISSN: 17431328     Source Type: Journal    
DOI: 10.1179/1743132811Y.0000000018     Document Type: Article

References (34)

1. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet 1998;352:1245-51.
2. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
3. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995;333:1581-7.
4. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
5. Albers GW, Bates VE, Clark WM, Bell R, Verro P, Hamilton SA. Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000;283:1145-50.
6. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847-50.
7. Grotta JC, Burgin WS, El-Mitwalli A, Long M, Campbell M, Morgenstern LB, et al. Intravenous tissue-type plasminogen activator therapy for ischemic stroke: Houston experience 1996 to 2000. Arch Neurol 2001;58:2009-13.
8. Wang Y, Tsirka S, Strickland S, Stieg P, Soriano S, Lipton S. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4:228-31.
9. Armstead WM, Nassar T, Akkawi S, Smith DH, Chen XH, Cines DB, et al. Neutralizing the neurotoxic effects of exogenous and endogenous tPA. Nat Neurosci 2006;9:1150-5.
10. Abu Fanne R, Nassar T, Yarovoi S, Rayan A, Lamensdorf I, Karakoveski M, et al. Blood-brain barrier permeability and tPA-mediated neurotoxicity. Neuropharmacology 2010;58:972-80.
11. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degan J, Bronson R, et al. Physiological consequences of loss of plasminogen activator gene function in mice. Nature 1994;368:419-24.
12. Bdeir K, Murciano JC, Tomaszewski J, Koniares L, Martinez J, Cines DB, et al. Urokinase mediates fibrinolysis in the pulmonary microvasculature. Blood 2000;96:1820-6.
13. Tabrizi P, Wang L, Seeds N, McComb JG, Yamada S, Griffin JH, et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model. Arterioscler Thromb Vasc Biol 1999;19:2801-6.
14. Mori T, Wang X, Kline AE, Siao CJ, Dixon CE, Tsirka SE, et al. Reduced cortical injury and edema in tissue plasminogen activator knockout mice after brain trauma. Neuroreport 2001;12:4117-20.
15. Abe Y, Nakamura H, Yoshino O. Decreased neural damage after spinal cord injury in tPA-deficient mice. J Neurotrauma 2003;20:43-57.
16. Nagai N, Vlinthout D, Collen D. Comparative effects of tissue plasminogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation 1999;100:2541-6.
17. Collen D. Novel approaches to fibrinolysis for stroke. in Proceedings of the 23rd Princeton Conference on 'Cerebrovascular disease'; 2002 Mar 21-23; Coronado, CA, USA. San Diego, CA: University of California; 2002.
18. Nassar T, Akkawi S, Shina A, Haj-Yehia A, Bdeir K, Tarshis M, et al. In vitro and in vivo effects of tPA and PAI-1 on blood vessel tone. Blood 2004;103:897-902.
19. Armstead WM, Cines DB, Higazi AA. Plasminogen activators contribute to impairment of hypercapnic and hypotensive cerebrovasodilation after cerebral hypoxia/ischemia in the newborn pig. Stroke 2005;36:2265-9.
20. Armstead WM, Cines DB, Higazi AA. Altered NO function contributes to impairment of uPA and tPA cerebrovasodilatation after brain injury. J Neurotrauma 2004;21:1204-11.
21. Kuiper J, Otter M, Voorschuur A, van Zonneveld A, Rijken D, van Berkel T. Thromb Haemost 1995;74:1298-304.
22. Reilly TM, Mousa SA, Seetharam R, Racanelli AL. Recombinant plasminogen activator inhibitor type 1: a review of structural, functional, and biological aspects. Blood Coagul Fibrinolysis 1994;5:73-81.
23. Madison EL, Goldsmith EJ, Gerard RD, Gething MJH, Sambrook JF, Bassel-Duby RS. Amino acid residues that affect interaction of tissue plasminogen activator with plasminogen activator inhibitor. Proc Natl Acad Sci USA 1990;87:3530-4.
24. Zhang L, Strickland DK, Cines DB, Higazi AAR. Regulation of single chain urokinase binding, internalization, and degradation by a plasminogen activator inhibitor 1-derived peptide. J Biol Chem 1997;272:27053-7.
25. Kudo M, Aoyama A, Ichimori S, Fukunaga N. An animal model of cerebral infarction: homologous blood clot emboli in rats. Stroke 1982;13:505-10.
26. Meng W, Wang X, Asahi M, Kano T, Asahi K, Ackerman RH, et al. Effects of tissue type plasminogen activator in embolic versus mechanical model of focal cerebral ischemia in rats. J Cereb Blood Flow Metab 1999;19:1316-21.
27. Chen J, Sanberg PR, Li Y, Wang L, Lu M, Willing AE, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke 2001;32:2682-8.
28. Petullo D, Masonic K, Lincoln C, Wibberley L, Teliska M, Yao DL. Model development and behavioral assessment of focal cerebral ischemia in rats. Life Sci 1999;64:1099-108.
29. Tejima E, Katayama Y, Suzuki Y, Kano T, Lo EH. Hemorrhagic transformation after Fibrinolysis with tissue plasminogen activator: Evaluation of role of hypertension with thromboembolic stroke model. Stroke 2001;32:1336-40.
30. Shuaib A, Xu Wang C, Yang T, Noor R. Effects of neuropeptide V1 vasopressin receptor antagonist SR-49059 on infarction volume and recovery of function in focal embolic stroke model. Stroke 2002;33:3033-7.
31. Zhang ZG, Zhang RL, Jiang Q, Raman SB, Cantwell L, Chopp M. A new rat model of thrombotic focal cerebral ischemia. J Cereb Blood Flow Metab 1997;17:123-35.
32. Armstead WM, Cines DB, Higazi AA. Plasminogen activators contribute to age-dependent impairment of NMDA cerebrovasodilation after brain injury. Dev Brain Res 2005;156:139-46.
33. Armstead WM, Cines DB, Bdeir K, Kulikovskaya I, Stein SC, Higazi AA. uPA impairs cerebrovasodilation after hypoxia/ ischemia through LRP and ERK MAPK. Brain Res 2008;1231:121-31.
34. Nicole O, Docagne F, Ali C, Margaill I, Carmeliet P, MacKenzie ET, et al. The proteolytic activity of tissueplasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001;7:59-64.